Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michelle Mangual Garcia

Endocrinology, Diabetes & Metabolism San Juan, PR Medical Doctor

NPI 1518292960 CMS profile 605795

Ave. Loma Verdes Carr 177, 1724 Yangtze, Rio Piedras Heights, San Juan, PR 00926

Open in the dashboard

General payments

$87,217

793 records reported · program years 2019–2025

Research payments

$14,716

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$656,226 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Michelle Mangual Garcia of San Juan, PR is reported in the CMS Open Payments database as having received $87,217 across 793 general payments and $14,716 in research payments paid to them. Separately, studies naming them as principal investigator received $656,226 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,265 85
2024 General $4,522 111
2024 Research $2,900 1
2023 General $3,624 116
2022 General $4,368 124
2022 Research $3,999 2
2021 General $9,432 123
2021 Research $6,344 2
2020 General $28,847 115
2020 Research $1,473 1
2019 General $30,160 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Mangual Garcia
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Michelle Mangual Garcia were reported at $6,265. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Michelle Mangual Garcia Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $30,160 $494 $123–$2,253 $163
2020 $28,847 $335 $85–$1,841 $114
2021 $9,432 $398 $88–$1,981 $132
2022 $4,368 $364 $88–$1,568 $149
2023 $3,624 $420 $113–$1,614 $160
2024 $4,522 $440 $121–$1,646 $164
2025 $6,265 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $24,749 107 payments
  2. Lilly USA, LLC $23,647 40 payments
  3. Eli Lilly Export S.A. Puerto Rico Branch $11,775 63 payments
  4. Merck Sharp & Dohme Corporation $6,779 49 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $3,363 95 payments
  6. Janssen Pharmaceuticals, Inc $3,057 34 payments
  7. Sanofi-Aventis U.S. LLC $2,759 64 payments
  8. Amgen Inc. $2,511 42 payments
  9. Medtronic, Inc. $1,355 22 payments
  10. Novo Nordisk Inc $1,194 57 payments
  11. Other $6,027 220 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $49,713 54 payments
  2. Food and Beverage $23,514 704 payments
  3. Travel and Lodging $7,912 30 payments
  4. Consulting Fee $6,070 3 payments
  5. Education $9 2 payments
Products named General payments · program years 2019–2025
  1. TRULICITY $34,256 64 payments
  2. FARXIGA $23,875 76 payments
  3. INVOKANA $2,651 22 payments
  4. JARDIANCE $2,582 68 payments
  5. SOLIQUA 100/33 $1,715 29 payments
  6. TOUJEO $1,631 18 payments
  7. Kerendia $1,414 39 payments
  8. STEGLATRO $1,299 13 payments
  9. Repatha $1,166 21 payments
  10. EVENITY $1,085 24 payments
  11. Other $15,902 614 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $11,816 5 payments
  2. Eli Lilly Export S.A. Puerto Rico Branch $2,900 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

5,838

Median for Internal Medicine: 777

Drug cost

$2,382,690

Median for Internal Medicine: $73,373

Branded share of claims

69.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 438 $467,449
Ozempic Semaglutide Brand 428 $435,514
Mounjaro Tirzepatide Brand 206 $227,592
Trijardy Xr Empaglifloz/Linaglip/Metformin Brand 271 $201,602
Synjardy Xr Empagliflozin/Metformin Hcl Brand 167 $131,476
Glyxambi Empagliflozin/Linagliptin Brand 130 $93,289
Jardiance Empagliflozin Brand 99 $89,421
Farxiga Dapagliflozin Propanediol Brand 108 $83,260
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 132 $80,841
Rybelsus Semaglutide Brand 74 $75,968

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$11,467

Medicare's payments for the services billed

Medicare patients

59

Average age 75

Services billed

166

39 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 56%
Arthritis 44%
Osteoporosis 29%
Ischemic heart disease 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $324
  • Eli Lilly Export S.A. Puerto Rico Branch $83
  • Lilly USA, LLC $31
$438 99 —
Kerendia
  • Bayer Puerto Rico Inc. $173
  • Bayer HealthCare Pharmaceuticals Inc. $121
$294 27 —
MOUNJARO
  • Lilly USA, LLC $119
  • Eli Lilly Export S.A. Puerto Rico Branch $96
$215 206 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $192
$192 — —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $173
$173 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

799 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record